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A B S T R A C T   
Background: Not all patients respond well to early interventions for their psychosis. The present study's goal was 
to evaluate whether patients' responses in the first six months of treatment in a specialised three-year programme 
could predict final outcomes. 
Methods: 206 early psychosis patients were assessed at baseline, using a large set of sociodemographic and 
clinical variables, and then monitored for 36 months. Among those variables, changes in their Global Assessment 
of Functioning (GAF) scores during the first six months were used to predict outcomes after three years. 
Results: Changes in GAF scores during the first six months were the only variables that predicted every symptom 
of functional outcome. GAF scores were also always the first or second most important predictor for every 
outcome. This finding held for both high- and low-functioning patients at baseline. 
Conclusions: Predicting poor long-term outcomes after only six months should help clinicians to improve 
treatments.   
1. Introduction 
Early intervention is now widely seen as a standard approach to 
treating psychotic disorders. Early identification, reducing the duration 
of untreated psychosis (DUP) and reinforcing treatment adherence are 
some of its main goals (Conus et al., 2010; Golay et al., 2016; Malla et al., 
2002; Sheitman et al., 1997). Case management interventions is an 
essential ingredient of most programs (Marshall et al., 2004). Case- 
management has progressively developed during the last decades and 
the responsibility of clinicians assuming such positions in early inter-
vention programs is to facilitate patient's engagement, conduct clinical 
assessment, plan treatment in collaboration with psychiatrists, facilitate 
linkage with available treatment resources, collaborate with families, 
and provide psychoeducation or crisis intervention (Alameda et al., 
2016; Lamb, 1980; Marion-Veyron et al., 2013). Despite the recognised 
effectiveness of early intervention, not all patients reach favourable 
symptomatic or functional outcomes at the end of their programme and 
service disengagement in the context of early psychosis remains a high 
stake issue (Edwards et al., 2002; Golay et al., 2020; Robinson et al., 
2004). Indeed, about a fifth of patients with recent-onset schizophrenia 
have persistent psychotic symptoms and experience disability, suffering 
and family burden (Edwards et al., 2002). Stratification tools are needed 
to personalize prevention strategies at an early stage. The goal is to 
improve patient response to treatment and counteracting the functional 
deficits that critically affect their long-term quality of life (Fournier 
et al., 2020). 
Recent studies in large representative cohorts of early psychosis (EP) 
patients showed that functional impairment is prevalent in patients with 
EP and that the longitudinal course of functioning in the early stage of 
psychotic illness remains under-studied (Chang et al., 2018; Hall et al., 
2019; Hodgekins et al., 2015). These studies also revealed the hetero-
geneous courses of socio-occupational functioning during EP, with 
distinct functional trajectories. In particular, Chang et al. (2018) re-
ported that approximately half of the patients displayed a persistently 
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poor trajectory over three years, suggesting that socio-occupational 
impairment had been an unmet therapeutic need in the early phase of 
their illness. This is in line with the critical period hypothesis, suggesting 
that symptoms during the first two or three years are important for long- 
term prognosis (Birchwood et al., 1998). However, another recent study 
suggested that long-term prognosis can be predicted much sooner—as 
early as one year after the first psychotic episode (Simonsen et al., 
2017). This suggests that factors that could predict poor outcomes could 
be identified early during treatment, allowing the adjustment of thera-
peutic strategies. More importantly, there is a need to test if considering 
the dynamic of change of certain variables rather than their cross 
sectional value is a better approach for the identification of patients at 
risk of poor evolution. In a neighbouring field, it has been shown, for 
instance, that increase in patient weight during the first month of 
treatment with second-generation antipsychotics predicted longer-term 
weight gain (Vandenberghe et al., 2018); following the same rationale, 
the present study's goal was to investigate whether changes in global 
functioning within the first six months of a specialised EP intervention 
programme could predict various outcomes after three years. The 6- 
months timeframe was chosen to ensure case-managers had enough 
time to meet patients several times after a first hospitalisation. Specif-
ically, this 6-months period from the first admission of our programme 
was chosen as the best time point on clinical grounds to observe the 
initial changes in our population: in this interval, case-managers are able 
to establish and stabilise the basis of the alliance, have contacted the 
relevant partners in the patient's network, have planned the initial 
therapeutic goals and have clarified the intensity of the intervention or 
the need for an intensive mobile intervention. In order to take advantage 
of the longitudinal cohort follow-up, we also used mid-programme 
outcomes (after 18 months). 
2. Material and methods 
2.1. Participants 
The Treatment and early Intervention in Psychosis Programme 
(TIPP) is a specialised EP programme run by Lausanne University Hos-
pital's Department of Psychiatry, in Switzerland (Baumann et al., 2013). 
Inclusion criteria are being aged from 18 to 35, living in the hospital's 
catchment area (population about 350,000) and meeting the criteria for 
psychosis as defined by the ‘psychosis threshold’ subscale in the 
Comprehensive Assessment of At-Risk Mental States (CAARMS) instru-
ment (Yung et al., 2005). This psychotic disorder threshold is defined as 
frank psychotic symptoms such as delusions, hallucinations and thought 
disorder persisting for longer than one week and with a frequency of at 
least 3-6 times a week for longer than one hour each time or daily for less 
than 1 h each time. This is a standard and widely used criteria for first 
episode psychosis threshold (Nelson et al., 2014). 
Patients with psychosis related to intoxication or an organic brain 
disease, an IQ < 70, or who have been taking antipsychotic medication 
for more than six months are referred to other programmes. Patients can 
be referred in several ways: general practitioners, families, private 
psychiatrists, psychiatric institutions, the Psychiatry Liaison Service and 
other Lausanne University Hospital departments (e.g. emergency, psy-
chiatry) can all contact the TIPP team, who will conduct an initial 
assessment by email or telephone. A multidisciplinary team (including 
psychiatrists and case management nurses) ensures the accuracy of in-
clusion criteria before admitting patients. The TIPP rationale is based on 
the principles of both case management interventions and assertive 
community treatment undertaken in outpatient settings. Patients are 
seen at least 100 times over the three-year programme, primarily by 
their case manager but also by a resident physician or an intern in 
psychiatry. A consultant psychiatrist supervises each case. 
All patients treated within the TIPP are fully assessed at baseline, 
after two months, 6 months and then prospectively every six months in 
order to monitor outcomes and adjust treatments. A specially designed 
questionnaire (the TIPP Initial Assessment Tool: TIAT; available online; 
Service of General Psychiatry D.o.P., 2021) is completed for all patients 
enrolled in the programme by case managers. It allows assessment of 
demographic characteristics, past medical history, exposure to life 
events as well as symptoms and functioning. It is completed on the basis 
of information gathered from patients and their family over the first 
weeks of treatment and can be updated during follow up if new infor-
mation emerges. Follow-up assessments exploring various aspects of 
treatment and co-morbidities as well as evolution of psychopathology 
and functional level are conducted by a psychologist and by case man-
agers at baseline, after 2, 6, 12, 18, 24, 30 and 36 months in treatment. 
Symptoms assessment are conducted by a psychologist who is inde-
pendent of patients' treatment and had received standardized training. 
For three years, case managers are available to each patient up to twice a 
week. An Intensive Case Management team can provide additional 
support and treatment at any time during the treatment period. TIPP 
case managers remain involved, however, to ensure continuity of care. 
This study was carried out in accordance with the Declaration of Hel-
sinki and was approved by the Human Research Ethics Committee of the 
Canton of Vaud (CER-VD; protocol #2020-00272). Access to clinical 
data was granted for research purposes allowing the data generated 
during patient follow-up were used in the study. Consequently, all pa-
tients who received treatment within this programme could be included 
in this study. 
2.2. Clinical assessments 
Case managers and an experienced psychologist performed detailed 
evaluations of patients' using interviews and the TIAT questionnaire. 
The DUP was defined as the time between the onset of the psychotic 
symptoms defined by the CAARMS and admission to the TIPP. Patients' 
socioeconomic statuses were subdivided into low, intermediate and high 
(Chandola and Jenkinson, 2000). Premorbid functional level was eval-
uated using the Premorbid Adjustment Scale (PAS; Cannon-Spoor et al., 
1982). The Global Assessment of Functioning (GAF) instrument was 
used to assess functional levels at baseline, and changes between the six- 
month GAF assessments (ΔGAF 0–6 months) and baseline were also 
computed. A positive difference score indicated improvement in global 
functioning during the first six months of the follow-up. We focused on 
change in global functioning because this measure provides a broader 
picture of functioning, including the impact of symptomatology and 
social and professional functioning, and because it is easy to administer 
by clinicians. Its 1-100 scoring allows for a finer discrimination than 
other global scores with limited range. Insight into the illness was cat-
egorised as complete, partial or absent (Conus et al., 2007). Severity of 
illness at baseline was assessed using the Clinical Global Impression 
scale (CGI; Guy, 1976). Diagnosis results from an expert consensus 
discussed at 18 and 36months, based on the DSM-IV criteria using the 
information from medical reports from treating psychiatrists, as well as 
from the TIPP-assigned psychiatrist and case manager. In this study, we 
used the latest consensus diagnostic available. Past diagnosis of sub-
stance abuse/dependence was rated according to DSM-IV. 
2.3. Outcomes 
Functional characteristics after 18 months or at the end of the pro-
gramme were assessed using the Modified Vocational Status Index and 
the Modified Location Code Index while living independently (MVSI & 
MLCI; Tohen et al., 2000). Patients were considered as living indepen-
dently based on their MLCI score (head of household or living alone, 
living with a partner or peers, or living with their family with minimal 
supervision). Patients were considered as working at based on the MVSI 
(in paid or unpaid, full- or part-time employment, being an active stu-
dent in school or university, head of household with an employed 
partner (homemaker), or a full or part-time volunteer). Functional re-
covery after three years or 18 months was defined as a GAF score > 60. 
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Symptomatic remission at the end of the programme or after 18 months 
was defined by the last Positive And Negative Syndrome Scale assess-
ment score in the last year of the programme, following Andreasen's 
Criteria (mild or lower (≤3) score on the following items: delusion, 
unusual thought content, hallucinatory behaviour, conceptual disorga-
nization, mannerisms, blunted affect, social withdrawal & lack of 
spontaneity; Andreasen et al., 2005). The number of hospitalisations 
during the programme was calculated from patients' medical records. 
Insight into the illness was categorised as complete, partial or absent 
(Conus et al., 2007). Therefore, our study included seven dichotomous 
outcomes: work activity (MVSI), living independently (MLCI), working 
& living independently combined, functional recovery (GAF > 60), 
symptomatic remission, repeated hospitalisation during programme and 
full insight recovery. 
2.4. Statistical analysis 
A series of logistic regression models were estimated to predict the 
various outcomes. ΔGAF 0–6 months and other important baseline 
variables (age, sex, socioeconomic status, DUP, Premorbid Adjustment 
Scale, Clinical Global Impression at baseline, and diagnosis) were 
introduced as predictors. To compare the relative importance of 
different independent variables, differences in Nagelkerke's R squared 
were computed with each variable removed. Finally, because ΔGAF 0–6 
months was negatively correlated to baseline functioning, we also 
checked whether scores could predict outcomes for higher-functioning 
and lower-functioning patients at baseline; participants were split in 
to below- and above median subgroups based on their baseline GAF 
score. Models for all outcomes were re-estimated using baseline GAF and 
ΔGAF 0–6 months as predictors. 
3. Results 
A total of 206 patients was included. Sample characteristics are 
shown in Table 1. Patients were predominantly male (61.2%) with an 
average age of 24.4 years. Among the patients, 57.8% had a diagnostic 
of Schizophrenia, 10.7% of Brief schizophreniform disorder, 11.7% of 
Schizoaffective disorder, 8.3% of Major depression with psychotic fea-
tures, 8.3% of Bipolar disorder and 9.2% another diagnostic. A total of 
18 patients (8.7%) left the programme before the end of the three year 
period. Among them, 6 (33.3%) fulfilled the definition of “disengage-
ment” (patients actively refusing any contact with the treatment facility 
or that were not traceable despite extensive efforts). 
Results of the logistic regression models for the three-year outcomes 
are presented in Table 2. ΔGAF 0–6 months was the only variable that 
predicted all the other outcome variables: having a work activity 
(MVSI), living independently (MLCI), working & living independently 
combined, functional recovery (GAF > 60), symptomatic remission, 
repeated hospitalisation during programme, and full insight recovery. It 
was also always the first or second most important predictor of every 
outcome according to ΔR2. Baseline GAF also predicted every three-year 
outcome except symptomatic remission when other variables were 
taken into account. DUP and socioeconomic status predicted several but 
not every aspect of recovery (DUP predicted working & living inde-
pendently combined and symptomatic remission; socioeconomic status 
predicted work activity (MVSI) and working & living independently 
combined). Diagnosis only predicted working & living independently 
combined. 
Results for mid-programme outcomes after 18 months were very 
similar (Table 3). ΔGAF 0–6 months was the only variable that predicted 
all 18-months outcome variables. It was also always the first or second 
most important predictor of every outcome according to ΔR2. 
ΔGAF 0–6 months was negatively correlated with baseline GAF (r =
− 0.608, p < .001). Baseline GAF was rarely associated with outcomes 
within either the above- or below-median patient subgroups. However, 
ΔGAF 0–6 months could predict most outcomes in the different 
subgroups (Table 4). In the below-median subgroup, 23.8% of patients 
with a ΔGAF 0–6 months of 20 or below reached Functional recovery 
(GAF > 60) after 3 years, whereas this rose to 46.5% among those with 
ΔGAF 0–6 months over 20 (χ2(1) = 5.225, p = .022). The pattern was 
the same at mid-programme (22.6% vs 44.1%; χ2(1) = 4.831, p = .028). 
In the above-median subgroup, 54.3% of patients with a ΔGAF 0–6 
months of 20 or below reached Functional recovery (GAF > 60) after 3 
years, whereas this reached 100.0% of those with ΔGAF 0–6 months 
over 20 (Fisher's exact test, p = .020). At mid-programme, this pattern 
was less evident however (51.7% vs 85.7%, Fisher's exact test, p = .120). 
Finally, it should be noted that lifetime substance abuse (alcohol - χ2(1) 
= 7.906, p = .005, cannabis - χ2(1) = 5.012, p = .025 & other substances 
- χ2(1) = 5.663, p = .017) and lifetime substance addiction (alcohol - χ2 
(1) = 7.592, p = .006 & cannabis - χ2(1) = 11.648, p = .001) were 
significantly more frequent in the below-median subgroup. However, 
lifetime substance abuse and lifetime substance addition did not differ 
between patients with below-median ΔGAF 0–6 months (≤10.00) and 
above-median ΔGAF 0–6 months (>10.00) with the exception of alcohol 
abuse who was slightly more frequent when ΔGAF 0–6 months was 
above-median (χ2(1) = 4.111, p = .043). 
4. Discussion 
The present study investigated whether early changes in the global 
functioning of patients treated using a specialised EP intervention pro-
gramme could predict a series of outcomes at the end of that three-year 
programme. Overall, our results suggest that after only six months of 
treatment, initial changes in patients' GAF scores predict a variety of 
long-term symptomatic and functional outcomes. This adds support to 
Table 1 
Sample characteristics (N = 206).  
Characteristics 
Age, Mean (SD), year 24.55 (4.79) 
Sex, % (N), male 61.2 (126) 
Socioeconomic status, % (N)  
Low 17.0 (35) 
Intermediate 45.1 (93) 
High 37.9 (78) 
DUP, Median (IQR), days 103.00 (504.25) 
Age of onset, Mean (SD), year 23.12 (5.20) 
Premorbid Adjustment (PAS) 0.31 (0.17) 
CGI baseline, Mean (SD) 4.60 (1.36) 
GAF baseline, Mean (SD) 42.89 (16.96) 
GAF 2 months, Mean (SD) 49.39 (15.18) 
GAF 6 months, Mean (SD) 54.10 (14.99) 
GAF 12 months, Mean (SD) 56.82 (15.51) 
GAF 18 months, Mean (SD) 58.93 (14.63) 
GAF 24 months, Mean (SD) 58.63 (15.67) 
GAF 30 months, Mean (SD) 59.76 (15.90) 
GAF 36 months, Mean (SD) 59.71 (16.23) 
ΔGAF 0–6 months, Mean (SD) 11.20 (16.90) 
Diagnosis, % (N)  
Schizophrenia 57.8 (119) 
Brief schizophreniform disorder 10.7 (22) 
Schizoaffective disorder 11.7 (24) 
Major depression 2.4 (5) 
Bipolar disorder 8.3 (17) 
Others 9.2 (19) 
Lifetime substance abuse (DSM), % (N)  
Alcohol 22.6 (45) 
Cannabis 33.8 (68) 
Other substances 13.1 (27) 
Lifetime substance addiction (DSM), % (N)  
Alcohol 8.0 (16) 
Cannabis 27.5 (55) 
Other substances 6.8 (14) 
Insight at presentation, % (N)  
Absent 31.0 (62) 
Partial 42.5 (85) 
Complete 26.5 (53)  




Prediction of three-year outcomes.  
Outcomes after three 
years 
Work activity (MVSI) Living independently 
(MLCI) 
Working & living 
independently combined 
Functional recovery (GAF >
60) 
Symptomatic remission Repeated hospitalisation 
during programme 
Full insight recovery 
OR p ΔR2 if 
removed 
OR p ΔR2 if 
removed 
OR p ΔR2 if 
removed 
OR p ΔR2 if 
removed 
OR p ΔR2 if 
removed 
OR p ΔR2 if 
removed 
OR p ΔR2 if 
removed 
Predictors 
Age 0.980 0.634 0.001 1.107 0.011 0.043 0.996 0.934 0.000 1.009 0.812 0.000 1.055 0.347 0.008 0.972 0.433 0.004 1.018 0.634 0.001 
Sex 0.806 0.619 0.001 0.838 0.627 0.001 0.804 0.640 0.002 0.906 0.790 0.000 1.204 0.729 0.001 1.011 0.976 0.000 1.137 0.723 0.001 
Socioeconomic status 3.070 0.001 0.078 0.882 0.611 0.002 2.815 0.003 0.060 0.919 0.722 0.000 0.921 0.827 0.000 0.981 0.936 0.000 1.550 0.080 0.001 
DUPa 0.642 0.095 0.015 0.698 0.085 0.019 0.503 0.018 0.033 0.829 0.395 0.003 0.526 0.041 0.043 0.861 0.447 0.003 0.753 0.189 0.020 
PAS Premorbid 
Adjustment 
0.492 0.601 0.001 0.471 0.493 0.003 0.370 0.505 0.003 0.041 0.007 0.040 1.207 0.907 0.000 0.402 0.371 0.005 1.304 0.815 0.011 
CGI baseline 1.705 0.022 0.030 1.294 0.226 0.009 1.456 0.129 0.014 0.762 0.203 0.008 0.881 0.711 0.001 1.050 0.813 0.001 1.534 0.053 0.025 
GAF Baseline 1.139 <0.001 0.191 1.042 0.039 0.028 1.144 <0.001 0.170 1.066 0.002 0.057 1.051 0.122 0.022 0.938 0.001 0.064 1.078 0.001 0.047 
ΔGAF 0–6 months 1.074 <0.001 0.113 1.038 0.012 0.043 1.107 <0.001 0.194 1.055 <0.001 0.078 1.052 0.025 0.053 0.936 <0.001 0.142 1.038 0.009 0.093 
Diagnostic – 0.055 0.068 – 0.299 0.044 – 0.046 0.079 – 0.131 0.052 – 0.366 0.160 – 0.231 0.045 – 0.132 0.048 




1.261 0.739 – 5.192 0.050 – 0.713 0.648 – 0.374 0.141 – 1.644 0.651 – 0.961 0.948 – 0.765 0.665 – 
Schizoaffective 
disorder 
0.284 0.107 – 1.743 0.319 – 0.216 0.096 – 1.128 0.822 – 0.475 0.327 – 1.748 0.276 – 6.789 0.006 – 
Major depression 9.474 0.038 – 4.035 0.239 – 5.388 0.127 – 7.366 0.091 – 0.000 1.000 – 0.310 0.316 – 1.750 0.566 – 
Bipolar disorder 0.199 0.078 – 2.253 0.297 – 0.108 0.033 – 4.182 0.072 – 1.7*109 0.999 – 1.168 0.812 – 1.708 0.497 – 
Others 1.690 0.448 – 1.408 0.574 – 2.540 0.193 – 1.099 0.878 – 5.747 0.053 – 0.246 0.045 – 1.053 0.934 – 
Model summary 
(Nagelkerke R2) 
Total R2 = 0.437 Total R2 = 0.237 Total R2 = 0.460 Total R2 = 0.340 Total R2 = 0.427 Total R2 = 0.261 Total R2 = 0.229 
N included in model (% 
missing) 
181 (12.1) 181 (12.1) 181 (12.1) 194 (5.8) 98 (52.4) 202 (1.9) 174 (15.5) 
Note. a = test statistics were based on log10 (+ 1) transformed data because of extreme positive skewness; OR = Odds ratio; p = p-value; statistically significant coefficients are in bold. 
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Prediction of 18 months outcomes.  
Outcomes after three 
years 
Work activity (MVSI) Living independently 
(MLCI) 
Working & living 
independently combined 
Functional recovery (GAF >
60) 
Symptomatic remission Repeated hospitalisation 
during programme 
Full insight recovery 
OR p ΔR2 if 
removed 
OR p ΔR2 if 
removed 
OR p ΔR2 if 
removed 
OR p ΔR2 if 
removed 
OR p ΔR2 if 
removed 
OR p ΔR2 if 
removed 
OR p ΔR2 if 
removed 
Predictors 
Age 0.924 0.067 0.017 1.077 0.037 0.030 0.908 0.041 0.025 0.993 0.857 0.000 0.941 0.178 0.015 0.892 0.010 0.039 1.077 0.051 0.023 
Sex 2.020 0.100 0.014 0.871 0.684 0.001 1.866 0.169 0.011 1.464 0.352 0.004 1.522 0.344 0.007 1.250 0.569 0.002 1.509 0.262 0.008 
Socioeconomic status 1.257 0.432 0.003 1.023 0.919 0.000 1.268 0.457 0.003 0.889 0.661 0.001 0.996 0.989 0.000 1.267 0.363 0.004 1.285 0.304 0.006 
DUPa 1.045 0.862 0.001 0.788 0.223 0.010 0.759 0.317 0.006 0.998 0.995 0.000 0.748 0.249 0.011 0.848 0.439 0.003 0.679 0.075 0.019 
PAS Premorbid 
Adjustment 
0.269 0.328 0.005 0.700 0.724 0.001 0.208 0.294 0.006 0.117 0.101 0.013 0.200 0.245 0.011 0.152 0.094 0.015 8.170 0.064 0.021 
CGI baseline 0.697 0.161 0.010 1.234 0.277 0.008 0.868 0.594 0.002 0.908 0.695 0.001 1.039 0.881 0.000 0.986 0.952 0.000 1.492 0.073 0.020 
GAF Baseline 1.077 0.003 0.050 1.036 0.060 0.024 1.104 <0.001 0.089 1.118 <0.001 0.114 1.061 0.016 0.050 0.933 0.002 0.058 1.088 0.000 0.096 
ΔGAF 0–6 months 1.073 <0.001 0.097 1.041 0.004 0.061 1.090 <0.001 0.146 1.100 <0.001 0.040 1.058 0.001 0.106 0.920 0.000 0.179 1.040 0.007 0.046 
Diagnostic – 0.024 0.068 – 0.995 0.003 – 0.400 0.028 – 0.186 0.000 – 0.147 0.077 – 0.123 0.069 – 0.168 0.079 




3.444 0.094 – 1.132 0.837 – 0.924 0.911 – 0.860 0.842 – 0.847 0.841 – 0.380 0.199 – 1.933 0.293 – 
Schizoaffective 
disorder 
1.700 0.409 – 0.885 0.808 – 1.629 0.499 – 0.857 0.795 – 0.903 0.875 – 1.757 0.283 – 3.514 0.027 – 
Major depression 6.994 0.084 – 0.635 0.663 – 12.062 0.036 – 7.832 0.090 – 5.092 0.187 – 0.497 0.550 – 1.6*109 0.999 – 
Bipolar disorder 13.385 0.003 – 0.771 0.720 – 1.689 0.624 – 5.623 0.074 – 5.782 0.053 – 0.829 0.803 – 1.123 0.892 – 
Others 1.815 0.357 – 0.990 0.986 – 1.909 0.363 – 0.485 0.292 – 5.338 0.066 – 0.077 0.019 – 0.545 0.326 – 
Model summary 
(Nagelkerke R2) 
Total R2 = 0.470 Total R2 = 0.125 Total R2 = 0.436 Total R2 = 0.472 Total R2 = 0.304 Total R2 = 0.342 Total R2 = 0.300 
N included in model (% 
missing) 
191 (7.3) 189 (8.3) 189 (8.3) 190 (7.8) 132 (64.1) 202 (1.9) 180 (12.6) 
Note. a = test statistics were based on log10 (+ 1) transformed data because of extreme positive skewness; OR = Odds ratio; p = p-value; statistically significant coefficients are in bold. 
P. G
olay et al.                                                                                                                                                                                                                                   
Schizophrenia Research 238 (2021) 62–69
67
the hypothesis that relying on dynamic changes, rather than on static 
variables, is a more suitable means of estimating patients' potential 
outcomes, and that early changes in functional levels are more reliable 
than any other baseline characteristic. 
Among patients with higher baseline functional levels, and despite 
limited scope for potential improvements, post hoc analyses showed that 
ΔGAF 0–6 months was still a good predictor of 18 months and three-year 
outcomes. This suggests that our findings may be generalisable to most 
patients, regardless of their functional level when entering the pro-
gramme. This variable may therefore prove to be a useful tool for the 
early detection of patients at risk of poorer outcomes and who may have 
special needs during the programme or require adjustments to their 
treatment. Some strategies (such as TREAT at EPPIC/ORYGEN) have 
been explicitly implemented within early intervention programmes to 
ensure prompt action when facing delayed recovery in patients with EP 
(Thien et al., 2018). Individuals with persistent positive symptoms at 12 
weeks are presented to the TREAT panel to implement intensive support 
and treatment adjustments for promoting a better recovery (Thien et al., 
2018). Our study confirms that discerning early changes in GAF scores 
could be helpful in the very early identification of subgroups of EP pa-
tients whose recovery would involve special treatment needs. 
Otherwise, baseline GAF scores were strong predictors of various 
outcomes and revealed a strong autoregressive structure to functional 
recovery. Patients' relative functioning rankings remained quite similar 
throughout the programme. In other words, patients with the lowest 
initial functioning scores are also likely to be among the lowest func-
tioning individuals at the end of the programme. Although a previous 
study reported that patients on a good functional trajectory might also 
have good functional outcomes at follow-up, it also reported a subgroup 
of patients with greater difficulties at treatment programme entry but an 
ability to recover quickly and reach good functional outcomes (Hall 
et al., 2019). This subgroup included more female, Caucasian subjects 
with higher socioeconomic status, a higher IQ, higher executive func-
tioning, better premorbid adjustment scale scores and a history of lower 
rates of substance use than the subgroup with poor functional trajec-
tories and outcomes. This suggests that the predictive value of the 
baseline GAF score might also depend on patients' characteristics, but 
further investigations will be required to better identify such subgroups. 
DUP and socioeconomic status predicted several but not all aspects of 
recovery. Although shortening the DUP is a key goal in early interven-
tion strategies, its predictive value for outcomes has been questioned 
(Golay et al., 2016; Polari et al., 2011). The DUP's limited predictive 
value for outcomes in previous studies was likely linked to problems of 
definition that did not consider adherence to treatment: when the end of 
the DUP is defined as the start of adherence to proper treatment, the 
DUP's predictive power is greater. In the present study, DUP was also 
competing with several other important variables explaining the lion's 
share of outcome variance. Considering that the DUP predicted working 
& living independently combined and symptomatic remission better 
than other variables did, efforts to shorten the DUP should continue, 
both through early detection and the development of engagement 
strategies. 
Some factors only predicted functional outcomes. In particular, 
premorbid functioning was only associated with functional recovery. 
This result was not surprising given that a recent study found that Pre-
morbid functioning had no predictive effect for remission (Simonsen 
et al., 2017). Moreover, socioeconomic status predicted a return to 
employment. With this in mind, new sociopolitical strategies must be 
implemented to better protect the professional status or employment of 
patients who develop psychosis (Dutoit et al., 2014). Finally, diagnosis 
only predicted working & living independently combined, which was in 
line with a previous study reporting the weak predictive value of di-
agnoses (Hall et al., 2019). In our opinion, these findings make a case for 
a multi-dimensional rather than a categorical or rules-based approach to 
diagnosis in psychiatry. Another study also recently suggested that 
combining symptom-dimensional scores for EP with a categorical 
diagnosis, rather than relying on diagnosis alone, improved the accuracy 
of predicting time to first remission (Ajnakina et al., 2018). 
This study had some limitations. First, our sample size was moderate, 
and further research should attempt to replicate our results in larger 
samples. Second, our results only suggest that treatment should be 
adjusted, but not how. It should also be highlighted that is a naturalistic 
study and as these individuals were not improving, they likely did 
receive more intensive inputs from their case-managers. Further study is 
therefore required to understand more specifically how and which ele-
ments of treatment should be adjusted or added when a rapid response is 
absent at the beginning of an early intervention programme. Second, 
Panss scores were not collected at baseline and were therefore not used 
in the analysis. Third, even if our models included several important 
variables, they did not include every potential confounding factors. 
Indeed, for statistical reasons, our models would likely be over- 
parametrized given our sample size. It could include change of 
Table 4 


















Outcomes after three years 
Below median Baseline GAF (≤ 40) subgroup, N = 101 
GAF 




x x x x x x x 
Above median baseline GAF (> 40) subgroup, N = 105 
GAF 
Baseline 
x  x x   x 
ΔGAF 0–6 
months 
x  x x  x x 
Outcomes after 18 months 
Below median Baseline GAF (≤ 40) subgroup, N = 101 
GAF 
Baseline   
x x   x 
ΔGAF 0–6 
months 
x x x x x x x 
Above median baseline GAF (>40) subgroup, N = 105 
GAF Baseline x  x x x   
ΔGAF 0–6 
months 
x  x x  x  
Note. x = significant predictor. 
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medication during the course of program, change of symptom severity 
and type of symptoms (positive, negative, affective, etc.), subset of pa-
tients receiving cognitive remediation training, substance use or case- 
manager utilization and treatment intensity. Therefore, it is unknown 
whether they could provide an even better predictor of outcome than 
ΔGAF 0–6 months. It also seems relevant to suggest other approaches for 
future work. Interactions between ΔGAF 0–6 months and factors like 
DUP, socioeconomic status, medication, compliance, cognition and so-
cial cognition (Green, 2016; Green et al., 2000) or cognitive remediation 
training should also be studied to better understand the determinants of 
long-term outcomes. We hypothesize that the predictive value of ΔGAF 
0–6 months could likely be moderated by these variables and could be 
higher or lower depending on the situation. 
Finally, the emphasis on the dynamics of change, rather than on 
baseline or static variables, could be extended to variables other than 
functioning (e.g. psychopathology or CGI scores). ΔCGI scores were not 
used in the present study and the specificity of differences in functioning 
versus symptomatology remains to be studied, especially since GAF 
mixes both symptomatology and functioning. Even if they are relatively 
crude, we have no reason to believe ΔCGI scores could not also be used 
to successfully predict long-term outcome. 
In conclusion, the present study reports that rapid changes in overall 
functioning scores during EP could predict various clinical outcomes 
after three years. This finding could help to tailor specific interventions 
for EP patients according to the early dynamics in their overall func-
tioning. Early changes in GAF scores seem to be an effective and simple 
predictor of which patients might make an incomplete recovery and 
need adjustments to their treatment strategies as early as possible. 
Further studies will be required to explore such targeted intervention 
strategies and to specify their key determinants and relevant 
associations. 
Role of the funding source 
This study was supported by the Swiss National Science Foundation 
(#320030_122419 to P.C.), by the FNS SYNAPSY (#320030-158776) 
and institutional funding. PSB was financially supported by Leenaards 
Foundation. 
CRediT authorship contribution statement 
PG, RJ, and PK designed this study. PG analyzed and interpreted the 
data. PG, JR RJ PK and NM drafted the first version of the manuscript. 
AS and PC critically revised the manuscript for important intellectual 
content. All authors read and approved the final manuscript. 
Declaration of competing interest 
The authors declare no conflict of interest in relation to the subject of 
the study. 
Acknowledgment 
We wish to thank the case managers from the TIPP Program for their 
invaluable work for collecting this data over the years. We also express 
our gratitude to all patients for their enduring participation. 
References 
Ajnakina, O., Lally, J., Di Forti, M., Stilo, S.A., Kolliakou, A., Gardner-Sood, P., 
Dazzan, P., Pariante, C., Marques, T.R., Mondelli, V., 2018. Utilising symptom 
dimensions with diagnostic categories improves prediction of time to first remission 
in first-episode psychosis. Schizophr. Res. 193, 391–398. 
Alameda, L., Golay, P., Baumann, P., Morandi, S., Ferrari, C., Conus, P., Bonsack, C., 
2016. Assertive outreach for “difficult to engage” patients: a useful tool for a 
subgroup of patients in specialized early psychosis intervention programs. Psychiatry 
Res. 239, 212–219. 
Andreasen, N.C., Carpenter Jr., W.T., Kane, J.M., Lasser, R.A., Marder, S.R., 
Weinberger, D.R., 2005. Remission in schizophrenia: proposed criteria and rationale 
for consensus. Am. J. Psychiatr. 162 (3), 441–449. 
Baumann, P.S., Crespi, S., Marion-Veyron, R., Solida, A., Thonney, J., Favrod, J., 
Bonsack, C., Do, K.Q., Conus, P., 2013. Treatment and early intervention in psychosis 
program (TIPP-Lausanne): implementation of an early intervention programme for 
psychosis in Switzerland. Early Interv.Psychiatry 7 (3), 322–328. 
Birchwood, M., Todd, P., Jackson, C., 1998. Early intervention in psychosis: the critical 
period hypothesis. Br. J. Psychiatry 172 (S33), 53–59. 
Cannon-Spoor, H.E., Potkin, S.G., Wyatt, R.J., 1982. Measurement of premorbid 
adjustment in chronic schizophrenia. Schizophr. Bull. 8 (3), 470. 
Chandola, T., Jenkinson, C., 2000. The new UK National Statistics Socio-Economic 
Classification (NS-SEC); investigating social class differences in self-reported health 
status. J. Public Health 22 (2), 182–190. 
Chang, W.C., Chu, A.O.K., Kwong, V.W.Y., Wong, C.S.M., Hui, C.L.M., Chan, S.K.W., 
Lee, E.H.M., Chen, E.Y.H., 2018. Patterns and predictors of trajectories for social and 
occupational functioning in patients presenting with first-episode non-affective 
psychosis: a three-year follow-up study. Schizophr. Res. 197, 131–137. 
Conus, P., Cotton, S., Schimmelmann, B.G., McGorry, P.D., Lambert, M., 2007. The first- 
episode psychosis outcome study: premorbid and baseline characteristics of an 
epidemiological cohort of 661 first-episode psychosis patients, 1 (2), 191–200. 
Conus, P., Lambert, M., Cotton, S., Bonsack, C., McGorry, P.D., Schimmelmann, B.G., 
2010. Rate and predictors of service disengagement in an epidemiological first- 
episode psychosis cohort. Schizophr. Res. 118 (1–3), 256–263. 
Dutoit, M., Besse, C., Hausmann, P., Spagnoli, D., Bonsack, C., 2014. Une expérience de 
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